1
|
Varnier R, Moskal A, Bodelet C, Péron J, Lamort-Bouché M, Fassier JB, Dima AL, Viprey M. Implementing Indicators and Trajectories of Return to Work After Breast Cancer Diagnosis: A Mixed-Methods Study Using the French National Healthcare Insurance Database and Stakeholder Consultation. Clin Breast Cancer 2024; 24:e528-e538.e5. [PMID: 38719678 DOI: 10.1016/j.clbc.2024.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2024] [Revised: 04/03/2024] [Accepted: 04/05/2024] [Indexed: 07/28/2024]
Abstract
PURPOSE Return to work (RTW) is important for quality of life after breast cancer but its analysis at the population-level remains limited in France. This study aimed to implement Electronic Healthcare Data (EHD)-based indicators and trajectories to measure RTW after breast cancer diagnosis, and to examine stakeholders' perspectives regarding these indicators. METHODS We followed a mixed-methods approach that consisted of (i) implementing RTW indicators and identifying clusters of trajectories using state sequence analysis with data from a representative sample of the French National Health Data System and (ii) exploring, through qualitative focus group and interviews, stakeholders' perceptions on the interpretation, limitations, and utility of these indicators. RESULTS We extracted data from 317 women aged 25-55 years with a first diagnosis of early-stage breast cancer. The median number of sickness absence periods was 2 for a total of 434 days during the 3-year follow-up, and the median time to sustainable RTW was 240 days. Three clusters of RTW trajectories were identified: "early RTW" (49.5% of the population), "RTW after partial resumption" (37.5%) and "continuous compensation" (12.9%). Feedback from stakeholders highlighted the multi-factorial nature of RTW and underscored the added value of EHD for studying RTW, despite certain limitations. CONCLUSIONS We demonstrated the feasibility of calculating RTW indicators and identifying trajectories using the French National Health Data System. These indicators can serve as outcome measures in RTW promotion and provide a basis for designing targeted interventions for breast cancer survivors.
Collapse
Affiliation(s)
- Romain Varnier
- Research on Healthcare Performance (RESHAPE, Inserm U1290), Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69008, Lyon, France
| | - Aurélie Moskal
- Research on Healthcare Performance (RESHAPE, Inserm U1290), Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69008, Lyon, France
| | - Céline Bodelet
- Research on Healthcare Performance (RESHAPE, Inserm U1290), Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69008, Lyon, France
| | - Julien Péron
- Research on Healthcare Performance (RESHAPE, Inserm U1290), Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69008, Lyon, France; Department of Medical Oncology, Lyon Sud University Hospital, Hospices Civils de Lyon, 165 chemin du Grand Revoyet, 69600, Oullins, France
| | - Marion Lamort-Bouché
- Research on Healthcare Performance (RESHAPE, Inserm U1290), Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69008, Lyon, France
| | - Jean-Baptiste Fassier
- Unité mixte de recherche épidémiologique et de surveillance transport travail environnement (UMRESTTE, UMR T9405), Université Claude Bernard Lyon 1, 25 avenue François Mitterrand, 69500, Bron, France; Occupational Health and Medicine Department, Hospices Civils de Lyon, 165 chemin du Grand Revoyet, 69600, Oullins, France
| | - Alexandra L Dima
- Health Technology Assessment in Primary Care and Mental Health (PRISMA), Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública CIBERESP, Madrid, Spain; Avedis Donabedian Research Institute (FAD), Universitat Autònoma de Barcelona, 008037 Barcelona, Spain.
| | - Marie Viprey
- Research on Healthcare Performance (RESHAPE, Inserm U1290), Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69008, Lyon, France; Health Data Department, Hospices Civils de Lyon, 162 avenue Lacassagne, 69008, Lyon, France
| |
Collapse
|
2
|
Beydon M, Pinto S, De Rycke Y, Fautrel B, Mariette X, Seror R, Tubach F. Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study. THE LANCET REGIONAL HEALTH. EUROPE 2023; 35:100768. [PMID: 37954220 PMCID: PMC10637983 DOI: 10.1016/j.lanepe.2023.100768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 10/18/2023] [Accepted: 10/19/2023] [Indexed: 11/14/2023]
Abstract
Background Older studies uncovered an increased risk of cancer in patients with rheumatoid arthritis between 10% and 30% compared to the general population, with a lack of data concerning infrequent cancers. In recent year, major therapeutic breakthroughs might have affected this risk of cancer by mitigating disease activity or on the contrary by impairing antitumoral immune response. The objectives of this study are to compare cancer risk in patients with treated rheumatoid arthritis to the general population, in all treated patients and according to treatment exposure. Methods This is a nationwide population-based study within the French national claims database "Système National des Données de Santé" (SNDS) between January 1st 2010 and December 31st 2020, to estimate the age and sex-standardized incidence ratios of cancer (all sites and site specific) of treated rheumatoid arthritis patients, with the French population as reference (by use of the French Network of Population-Based Cancer Registries [FRANCIM]). Findings During the study period, 257,074 treated patients with rheumatoid arthritis contributed to a total of 2,098,238 person-years for the main analysis. The all-cancer risk was increased in rheumatoid arthritis patients, with a SIR (Standardized Incidence Ratio) of 1.20 (95% CI [1.17-1.23]). This risk was increased particularly for lung (SIR 1.41, 95% CI [1.36-1.46], bladder (SIR 2.38 95% CI [2.25-2.51]), cervix (SIR 1.80, 95% CI [1.62-2.01]), prostate (SIR 1.08, 95% CI [1.04, 1.13]) cancers, melanoma (SIR 1.37, 95% CI [1.29-1.46]), diffuse large B cell lymphoma (SIR 1.79, 95% CI [1.63-1.96], multiple myeloma (SIR 1.42, 95% CI [1.27-1.60]) and Hodgkin's lymphoma (SIR 2.73, 95% CI [2.31-3.23]). Some cancers were less frequent than in the general population such as pancreatic (SIR 0.90, 95% CI [0.83-0.97]) as well as breast and endometrial cancers (SIR 0.91, 95% CI [0.88-0.94] and SIR 0.77, 95% CI [0.71-0.84] respectively). Although we observed a modest but significant relative increase of all-cancer risk over-time in rheumatoid arthritis patients, there was a trend towards a decrease in risk of non-Hodgkin's lymphoma. Patients treated with rituximab were the patients displaying the highest risk of cancer. Interpretation Compared to the general population, treated rheumatoid arthritis patients were at greater risk of all-cancer and some site specific cancers, except for breast, pancreatic and endometrial cancers which were less frequent than in the general population. Funding This work was supported by unrestricted grants from the InCA (national institute against cancer) and AP-HP (Assistance Publique des Hôpitaux de Paris).
Collapse
Affiliation(s)
- Maxime Beydon
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75013, Paris, France
| | - Sandrine Pinto
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75013, Paris, France
| | - Yann De Rycke
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, F75013, Paris, France
| | - Bruno Fautrel
- Département de Rhumatologie, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France
| | - Xavier Mariette
- Département de Rhumatologie, Université Paris-Saclay, INSERM U1184, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France
| | - Raphaèle Seror
- Département de Rhumatologie, Université Paris-Saclay, INSERM U1184, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France
| | - Florence Tubach
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, F75013, Paris, France
| |
Collapse
|
3
|
Dardim K, Fernandes J, Panes A, Beisel J, Schmidt A, Wolfram J, Todorova L, Dubel L, Lobbedez T. Incidence, prevalence, and treatment of anemia of non-dialysis-dependent chronic kidney disease: A retrospective database study in France. PLoS One 2023; 18:e0287859. [PMID: 37406014 DOI: 10.1371/journal.pone.0287859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 06/14/2023] [Indexed: 07/07/2023] Open
Abstract
BACKGROUND Minimal data are available regarding the prevalence and incidence of anemia among patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) in France. METHODS This was a retrospective non-interventional study of patients with a record of NDD-CKD in the Echantillon Généraliste des Bénéficiaires (EGB) database between January 01, 2012, and December 31, 2017. The primary objective was to estimate the annual incidence and prevalence of anemia of NDD-CKD. Secondary objectives included description of the demographics and clinical characteristics of patients with NDD-CKD-related anemia. An exploratory objective was to use machine learning to identify patients from the general population that might have NDD-CKD but without a recorded ICD-10 diagnosis of CKD. RESULTS During 2012-2017, 9865 adult patients in the EGB database had confirmed NDD-CKD; of these, 49.1% (4848/9865) had anemia. From 2015 to 2017, estimates of incidence (108.7-114.7 per 1000 population) and prevalence (435.7-449.5 per 1000 population) of NDD-CKD-related anemia were stable. Less than half of patients with anemia of NDD-CKD were treated with oral iron, and approximately 15% were treated with erythropoiesis-stimulating agents. Based on adult French population projections in 2020 and an estimated prevalence rate in 2017 of 42.2 per 1000 population for confirmed plus possible NDD-CKD (as a proportion of the general French population), the estimated number of patients with possible NDD-CKD in France was 2,256,274, approximately five-fold greater than the number identified by diagnostic codes and hospitalizations. CONCLUSIONS Anemia of NDD-CKD was shown to be a constant long-term burden in France, and its apparent prevalence may still be significantly underestimated. Given the potential treatment gap, additional initiatives to better identify and treat NDD-CKD anemia may improve patient management and treatment outcomes.
Collapse
Affiliation(s)
- Karim Dardim
- Association Limousine pour l'Utilisation du Rein Artificiel à Domicile (ALURAD), Limoges, France
| | | | | | | | | | | | - Lora Todorova
- Astellas Pharma Europe B.V., Leiden, The Netherlands
| | | | | |
Collapse
|
4
|
Charkaoui M, Hajage D, Tubach F, Beaugerie L, Kirchgesner J. Impact of Anti-tumour Necrosis Factor Agents on the Risk of Colorectal Cancer in Patients with Ulcerative Colitis: Nationwide French Cohort Study. J Crohns Colitis 2022; 16:893-899. [PMID: 34657962 DOI: 10.1093/ecco-jcc/jjab184] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND AND AIMS Patients with ulcerative colitis [UC] are at increased risk of colorectal cancer. Anti-tumour necrosis factor agents [anti-TNF] aim to reduce chronic colonic inflammation and may lower the risk of colorectal cancer [CRC], but the impact of anti-TNF exposure has not yet been assessed in population-based cohort studies. The aim of this nationwide study was to assess the risk of CRC in patients with UC exposed to anti-TNF. METHODS Based on the French health insurance database, patients aged 18 years or older with a diagnosis of UC, previously exposed to or initiating immunosuppressive treatment, were followed from January 1, 2009, until December 31, 2018. The risk of CRC associated with anti-TNF exposure was assessed using marginal structural Cox proportional hazard models adjusting for baseline and time-varying comorbidities including primary sclerosing cholangitis, UC disease activity, colonoscopic surveillance, and other medications. RESULTS Among 32 403 patients with UC, 15 542 [48.0%] were exposed to anti-TNF. During a median follow-up of 6.1 years [198 249 person-years], 246 incident CRC occurred (incidence rate per 1000 person-years, 1.24; 95% confidence intrval [CI], 1.10-1.41). Whereas the risk of CRC associated with anti-TNF exposure was not decreased in the overall group of patients with UC (hazard ratio [HR], 0.85; 95% CI, 0.58-1.26), anti-TNF exposure was associated with a decreased risk of CRC in patients with long-standing colitis [disease duration ≥10 years] [HR, 0.41; 95% CI, 0.20-0.86]. CONCLUSIONS In a nationwide cohort of patients with UC, anti-TNF exposure was associated with a decreased risk of CRC in patients with long-standing colitis.
Collapse
Affiliation(s)
- Maeva Charkaoui
- AP-HP Sorbonne Université, Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France.,Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - David Hajage
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.,AP-HP Sorbonne Université, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie, Paris, France
| | - Florence Tubach
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.,AP-HP Sorbonne Université, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie, Paris, France
| | - Laurent Beaugerie
- AP-HP Sorbonne Université, Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France.,Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Julien Kirchgesner
- AP-HP Sorbonne Université, Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France.,Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| |
Collapse
|
5
|
Mansouri I, Raffray M, Lassalle M, de Vathaire F, Fresneau B, Fayech C, Lazareth H, Haddy N, Bayat S, Couchoud C. An algorithm for identifying chronic kidney disease in the French national health insurance claims database. Nephrol Ther 2022; 18:255-262. [DOI: 10.1016/j.nephro.2022.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Accepted: 03/11/2022] [Indexed: 10/17/2022]
|
6
|
Seror R, Lafourcade A, De Rycke Y, Pinto S, Castaneda J, Fautrel B, Mariette X, Tubach F. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. RMD Open 2022; 8:rmdopen-2021-002139. [PMID: 35738803 PMCID: PMC9226991 DOI: 10.1136/rmdopen-2021-002139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 05/22/2022] [Indexed: 11/15/2022] Open
Abstract
Objective To compare the risk of malignancy between patients with rheumatoid arthritis (RA) initiating their first biological disease-modifying antirheumatic drug (bDMARD) and those continuing conventional synthetic DMARDs (csDMARDs). Methods Nine-year historical Propensity Score (PS) matched cohort study within the French national healthcare database (87% of the French population; ~57 million people), including adults RA without malignancy. Exposures started with the first use of any systemic treatment (csDMARDs and/or bDMARDs). Incident users of bDMARDs were matched on a dynamic PS to patients continuing csDMARDs. Their risk of malignancy was compared by Cox model. Results From 1 January 2007 to 31 December 2014, 83 706 patients with RA started their first systemic treatment (63 837 remained on csDMARDs and 19 869 initiated a bDMARD during follow-up). After dynamic PS matching, 19 727 bDMARD initiators were compared with 19 727 RA remaining on csDMARDs. They did not statistically differ in risk of overall malignancies (HR 0.99 (95% CI 0.86 to 1.14)), solid cancer (HR 0.95 (95% CI 0.82 to 1.11)), nor lymphoma (HR 1.35 (95% CI 0.72 to 2.53)). Results were similar when bDMARDs were given as monotherapy or in association with csDMARDs. Analyses restricted to patients starting TNF inhibitor as first bDMARD compared with matched RA remaining on csDMARDs, provided similar results (HR for overall malignancy 1.03 (95% CI 0.88 to 1.21)). Sensitivity analyses, varying carry-over periods (up to 5 years) to define risk periods, provided similar results. Conclusions In this historical cohort study within the French nationwide healthcare database, the risk of overall, solid or haematological malignancies did not significantly differ between patients with RA initiating bDMARD and those continuing csDMARDs.
Collapse
Affiliation(s)
- Raphaele Seror
- Service de Rhumatologie, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Université Paris-Saclay, FHU CARE, Le Kremlin-Bicetre, France .,INSERM UMR 1184, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicetre, France
| | - Alexandre Lafourcade
- Centre de Pharmacoépidémiologie (Cephepi), AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France
| | - Yann De Rycke
- Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.,Institut Pierre Louis d'epidemiologie, Sorbonne University, INSERM UMR-S 1136, Paris, France
| | - Sandrine Pinto
- Institut Pierre Louis d'epidemiologie, Sorbonne University, INSERM UMR-S 1136, Paris, France
| | - Johann Castaneda
- Centre de Pharmacoépidémiologie (Cephepi), AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France
| | - Bruno Fautrel
- Institut Pierre Louis d'epidemiologie, Sorbonne University, INSERM UMR-S 1136, Paris, France.,Service de Rhumatologie, Sorbonne Université, AP-HP.Sorbonne Université, Hôpital Pitié Salpêtrière, Paris, France
| | - Xavier Mariette
- Service de Rhumatologie, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Université Paris-Saclay, FHU CARE, Le Kremlin-Bicetre, France.,INSERM UMR 1184, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicetre, France
| | - Florence Tubach
- Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.,Institut Pierre Louis d'epidemiologie, Sorbonne University, INSERM UMR-S 1136, Paris, France.,delete this affiliaton, Paris, France
| |
Collapse
|
7
|
Dumas E, Laot L, Coussy F, Grandal Rejo B, Daoud E, Laas E, Kassara A, Majdling A, Kabirian R, Jochum F, Gougis P, Michel S, Houzard S, Le Bihan-Benjamin C, Bousquet PJ, Hotton J, Azencott CA, Reyal F, Hamy AS. The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS). Cancers (Basel) 2022; 14:cancers14112671. [PMID: 35681651 PMCID: PMC9179405 DOI: 10.3390/cancers14112671] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Revised: 05/10/2022] [Accepted: 05/22/2022] [Indexed: 12/10/2022] Open
Abstract
Simple Summary Because of an important disparity of care pathways and quality of care among women diagnosed with an early-stage breast cancer, we aimed to create a unique cohort of patients including all French women aged 18 years or over, treated by surgery and registered in the general health insurance coverage plan. After aggregating and annotating medico-administrative data on 235,368 early breast cancer patients, we open up perspectives for research on adverse effects, morbidity, mortality, the monitoring of care consumption, or medical-economic studies. We describe data sources, inclusion, and exclusion criteria, basic descriptive analyses, and longitudinal trends over time. Abstract Background: Breast cancer (BC) is the most frequent cancer and the leading cause of cancer-related death in women. The French National Cancer Institute has created a national cancer cohort to promote cancer research and improve our understanding of cancer using the National Health Data System (SNDS) and amalgamating all cancer sites. So far, no detailed separate data are available for early BC. Objectives: To describe the creation of the French Early Breast Cancer Cohort (FRESH). Methods: All French women aged 18 years or over, with early-stage BC newly diagnosed between 1 January 2011 and 31 December 2017, treated by surgery, and registered in the general health insurance coverage plan were included in the cohort. Patients with suspected locoregional or distant metastases at diagnosis were excluded. BC treatments (surgery, chemotherapy, targeted therapy, radiotherapy, and endocrine therapy), and diagnostic procedures (biopsy, cytology, and imaging) were extracted from hospital discharge reports, outpatient care notes, or pharmacy drug delivery data. The BC subtype was inferred from the treatments received. Results: We included 235,368 patients with early BC in the cohort (median age: 60 years). The BC subtype distribution was as follows: luminal (80.2%), triple-negative (TNBC, 9.5%); HER2+ (10.3%), or unidentifiable (n = 44,388, 18.9% of the cohort). Most patients underwent radiotherapy (n = 200,685, 85.3%) and endocrine therapy (n = 165,655, 70.4%), and 38.3% (n = 90,252) received chemotherapy. Treatments and care pathways are described. Conclusions: The FRESH Cohort is an unprecedented population-based resource facilitating future large-scale real-life studies aiming to improve care pathways and quality of care for BC patients.
Collapse
Affiliation(s)
- Elise Dumas
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France; (E.D.); (B.G.R.); (E.D.); (A.K.); (F.J.); (P.G.); (F.R.)
- INSERM, U900, 75005 Paris, France;
- MINES ParisTech, CBIO-Centre for Computational Biology, PSL Research University, 75006 Paris, France
| | - Lucie Laot
- Department of Surgical Oncology, Institut Curie, University of Paris, 75005 Paris, France; (L.L.); (E.L.); (S.M.)
| | - Florence Coussy
- Department of Medical Oncology, Institut Curie, University of Paris, 75005 Paris, France;
| | - Beatriz Grandal Rejo
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France; (E.D.); (B.G.R.); (E.D.); (A.K.); (F.J.); (P.G.); (F.R.)
| | - Eric Daoud
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France; (E.D.); (B.G.R.); (E.D.); (A.K.); (F.J.); (P.G.); (F.R.)
- INRIA, DI/ENS, PSL Research University, 75006 Paris, France
| | - Enora Laas
- Department of Surgical Oncology, Institut Curie, University of Paris, 75005 Paris, France; (L.L.); (E.L.); (S.M.)
| | - Amyn Kassara
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France; (E.D.); (B.G.R.); (E.D.); (A.K.); (F.J.); (P.G.); (F.R.)
| | - Alena Majdling
- Centre René Hughenin, Medical Oncology Department, 92210 Saint Cloud, France; (A.M.); (R.K.)
| | - Rayan Kabirian
- Centre René Hughenin, Medical Oncology Department, 92210 Saint Cloud, France; (A.M.); (R.K.)
| | - Floriane Jochum
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France; (E.D.); (B.G.R.); (E.D.); (A.K.); (F.J.); (P.G.); (F.R.)
- Department of Gynecology, Strasbourg University Hospital, 67091 Strasbourg, France
| | - Paul Gougis
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France; (E.D.); (B.G.R.); (E.D.); (A.K.); (F.J.); (P.G.); (F.R.)
| | - Sophie Michel
- Department of Surgical Oncology, Institut Curie, University of Paris, 75005 Paris, France; (L.L.); (E.L.); (S.M.)
| | - Sophie Houzard
- Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 92100 Boulogne-Billancourt, France; (S.H.); (C.L.B.-B.); (P.-J.B.)
| | - Christine Le Bihan-Benjamin
- Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 92100 Boulogne-Billancourt, France; (S.H.); (C.L.B.-B.); (P.-J.B.)
| | - Philippe-Jean Bousquet
- Survey Data Science and Assessment Division, French National Cancer Institute (Institut National du Cancer INCa), 92100 Boulogne-Billancourt, France; (S.H.); (C.L.B.-B.); (P.-J.B.)
- Inserm, IRD, SESSTIM, Equipe Labellisée Ligue Contre le Cancer, Aix-Marseille Université, 13005 Marseille, France
| | - Judicaël Hotton
- Department of Surgery, Institut Jean Godinot, 51100 Reims, France;
| | - Chloé-Agathe Azencott
- INSERM, U900, 75005 Paris, France;
- MINES ParisTech, CBIO-Centre for Computational Biology, PSL Research University, 75006 Paris, France
- Institut Curie, PSL Research University, 75005 Paris, France
| | - Fabien Reyal
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France; (E.D.); (B.G.R.); (E.D.); (A.K.); (F.J.); (P.G.); (F.R.)
- Department of Surgical Oncology, Institut Curie, University of Paris, 75005 Paris, France; (L.L.); (E.L.); (S.M.)
- Department of Surgery, Institut Jean Godinot, 51100 Reims, France;
| | - Anne-Sophie Hamy
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, 75005 Paris, France; (E.D.); (B.G.R.); (E.D.); (A.K.); (F.J.); (P.G.); (F.R.)
- Centre René Hughenin, Medical Oncology Department, 92210 Saint Cloud, France; (A.M.); (R.K.)
- Correspondence:
| |
Collapse
|
8
|
Lassalle M, Le Tri T, Afchain P, Camus M, Kirchgesner J, Zureik M, Dray-Spira R. Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case-Control Study Based on the French National Health Data System (SNDS). Cancer Epidemiol Biomarkers Prev 2022; 31:662-669. [PMID: 34937794 PMCID: PMC9381101 DOI: 10.1158/1055-9965.epi-21-0786] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Revised: 09/15/2021] [Accepted: 12/13/2021] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Only a few studies investigated the association between proton pump inhibitor (PPI) use and pancreatic cancer, with inconsistent results. Moreover, these studies had a number of methodologic limitations. Our objective was to assess this association in a nationwide case-control study. METHODS We used the French National Health Data System (SNDS), covering 99% of the French population since 2006. Incident cases of pancreatic cancer, identified between 2014 and 2018, were matched with up to four controls on year of birth, sex, frequency of hospitalization within 8 years prior to index date, and department of residence. Associations between PPIs and pancreatic cancer were estimated using conditional logistic regression models adjusted for sociodemographic characteristics, risk factors of pancreatic cancer (including diabetes mellitus, tobacco-related diseases, and morbid obesity), and other comorbidities. RESULTS A total of 23,321 cases of pancreatic cancer (mean age, 69.8 years; 51.7% males) and 75,937 matched controls were included. Overall, 77.8% of cases and 75.5% of controls were PPI ever users. Ever (vs. never) PPI use was associated with an increased risk of pancreatic cancer [adjusted OR (aOR) = 1.05, 95% confidence interval (CI), 1.01-1.09]. A dose-response relationship was observed [1-30 cumulative defined daily dose (cDDD): aOR = 0.92, 95% CI, 0.87-0.97; 31-180 cDDD: aOR = 1.05, 95% CI, 1.00-1.11; 181-1,080 cDDD: aOR = 1.18, 95% CI, 1.12-1.24; >1,080 cDDD: aOR = 1.17, 95% CI, 1.10-1.23]. CONCLUSIONS On the basis of these findings, a slight increase in the risk of pancreatic cancer associated with high cumulative doses of PPIs cannot be excluded. IMPACT Given the overuse of PPIs, efforts should be continued to limit treatments to appropriate indications and durations.
Collapse
Affiliation(s)
- Marion Lassalle
- EPIPHARE, Epidemiology of Health Products [French National Agency for the Safety of Medicines and Health Products (ANSM), and French National Health Insurance (CNAM)], Saint-Denis, France
| | - Thien Le Tri
- EPIPHARE, Epidemiology of Health Products [French National Agency for the Safety of Medicines and Health Products (ANSM), and French National Health Insurance (CNAM)], Saint-Denis, France
| | - Pauline Afchain
- Medical Oncology Department, APHP, Hôpital Saint Antoine, Paris, France
| | - Marine Camus
- Sorbonne University, Centre de Recherche Saint Antoine, UMRS-938, Paris, France
- Digestive Endoscopy Department, APHP, Hôpital Saint Antoine, Paris, France
| | - Julien Kirchgesner
- Sorbonne University, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
- Department of Gastroenterology, APHP, Hôpital Saint-Antoine, Paris, France
| | - Mahmoud Zureik
- EPIPHARE, Epidemiology of Health Products [French National Agency for the Safety of Medicines and Health Products (ANSM), and French National Health Insurance (CNAM)], Saint-Denis, France
- Versailles Saint-Quentin-en-Yvelines University, Versailles, France
| | - Rosemary Dray-Spira
- EPIPHARE, Epidemiology of Health Products [French National Agency for the Safety of Medicines and Health Products (ANSM), and French National Health Insurance (CNAM)], Saint-Denis, France
| |
Collapse
|
9
|
Yang MS, Park M, Back JH, Lee GH, Shin JH, Kim K, Seo HJ, Kim YA. Validation of Cancer Diagnosis Based on the National Health Insurance Service Database versus the National Cancer Registry Database in Korea. Cancer Res Treat 2021; 54:352-361. [PMID: 34353000 PMCID: PMC9016317 DOI: 10.4143/crt.2021.044] [Citation(s) in RCA: 50] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2021] [Accepted: 07/23/2021] [Indexed: 11/21/2022] Open
Abstract
Purpose This study aimed to assess the feasibility of operational definitions of cancer patients in conducting cancer-related studies using the claims data from the National Health Insurance Service (NHIS). Materials and Methods Cancer incidence data were obtained from The Korean Central Cancer Registry (KCCR), NHIS primary diagnosis, and from the rare and intractable disease (RID) registration program. Results The operational definition with higher sensitivity for cancer patient verification was different by cancer type. Using primary diagnosis, the lowest sensitivity was found in colorectal cancer (91.5%; 95% confidence interval [CI], 91.7 to 92.0) and the highest sensitivity was found in breast cancer (97.9%; 95% CI, 97.8 to 98.0). With RID, sensitivity was the lowest in liver cancer (91.9%; 95% CI, 91.7 to 92.0) and highest in breast cancer (98.1%; 95% CI, 98.0 to 98.2). In terms of the difference in the date of diagnosis in the cancer registration data, > 80% of the patients showed a < 31-day difference from the RID definition. Conclusion Based on the health claims data, the operational definition of cancer incidence is more accurate when using the RID registration program claims compared to using the primary diagnosis despite the relatively less concordance by cancer type requires additional definitions such as treatment.
Collapse
Affiliation(s)
- Min Soo Yang
- National Cancer Control Institute, National Cancer Center, Goyang, Korea
| | - Minae Park
- National Cancer Control Institute, National Cancer Center, Goyang, Korea
| | - Joung Hwan Back
- Health Insurance Policy Research Institute, National Health Insurance Service, Wonju, Korea
| | - Gyeong Hyeon Lee
- National Cancer Control Institute, National Cancer Center, Goyang, Korea
| | - Ji Hye Shin
- National Cancer Control Institute, National Cancer Center, Goyang, Korea
| | - Kyuwoong Kim
- National Cancer Control Institute, National Cancer Center, Goyang, Korea
| | - Hwa Jeong Seo
- Medical Informatics and health Technology (MIT), Department of Health Care Management, Gachon University, Seongnam, Korea
| | - Young Ae Kim
- National Cancer Control Institute, National Cancer Center, Goyang, Korea
| |
Collapse
|
10
|
Casarotto E, Noize P, Gouverneur A, Berdaï D, Bégaud B, Levy‐Bachelot L, Molimard M. Overview of French databases available for studying anticancer drugs in real‐life setting. Fundam Clin Pharmacol 2020; 35:76-85. [DOI: 10.1111/fcp.12592] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 06/15/2020] [Accepted: 07/27/2020] [Indexed: 12/19/2022]
Affiliation(s)
- Emilie Casarotto
- Univ. Bordeaux, INSERM, BPH, U1219 Bordeaux F‐33000 France
- MSD France Puteaux F‐92800 France
| | - Pernelle Noize
- Univ. Bordeaux, INSERM, BPH, U1219 Bordeaux F‐33000 France
- Service de Pharmacologie médicale Pôle de Santé Publique CHU de Bordeaux Bordeaux F‐33000 France
| | - Amandine Gouverneur
- Univ. Bordeaux, INSERM, BPH, U1219 Bordeaux F‐33000 France
- Service de Pharmacologie médicale Pôle de Santé Publique CHU de Bordeaux Bordeaux F‐33000 France
| | - Driss Berdaï
- Service de Pharmacologie médicale Pôle de Santé Publique CHU de Bordeaux Bordeaux F‐33000 France
| | - Bernard Bégaud
- Univ. Bordeaux, INSERM, BPH, U1219 Bordeaux F‐33000 France
| | | | - Mathieu Molimard
- Univ. Bordeaux, INSERM, BPH, U1219 Bordeaux F‐33000 France
- Service de Pharmacologie médicale Pôle de Santé Publique CHU de Bordeaux Bordeaux F‐33000 France
| |
Collapse
|
11
|
Shi C, Liu M, Liu Z, Guo C, Li F, Xu R, Liu F, Liu Y, Li J, Cai H, He Z, Ke Y. Using health insurance reimbursement data to identify incident cancer cases. J Clin Epidemiol 2019; 114:141-149. [DOI: 10.1016/j.jclinepi.2019.06.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 05/16/2019] [Accepted: 06/12/2019] [Indexed: 11/29/2022]
|
12
|
Ajrouche A, Estellat C, De Rycke Y, Tubach F. Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population. J Cardiovasc Pharmacol Ther 2019; 25:37-46. [PMID: 31339341 DOI: 10.1177/1074248419865287] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Previous studies have shown that adherence to low-dose aspirin (LDA) is suboptimal. However, these studies were based on an average measure of adherence during follow-up, ignoring its dynamic process over time. We described the trajectories of adherence to LDA treatment among the French population over 3 years of follow-up. METHODS We identified a cohort of 11 793 new LDA users, aged ≥50 years in 2010, by using the French national health-care database. Patients included had at least 3 years of history in the database before study entry to exclude prevalent aspirin users and to assess baseline comorbidities. They were followed from the first date of LDA supply (the index date) until the first date among death, exit from the database, or 3 years after the index date. Adherence to LDA was assessed every 3 months by using the proportion of days covered (PDC) and dichotomized with a cutoff of PDC of 0.8. We used group-based trajectory modeling to identify trajectories of LDA adherence. Predictors of LDA adherence trajectory membership were identified by multinomial logistics regression. RESULTS We identified 4 trajectories of adherence among new LDA users: the not-adherents (4737 [40.2%]), the delayed not-adherents (gradual decrease in adherence probability, 1601 [13.6%]), the delayed adherents (gradual increase in adherence probability, 1137 [9.6%]), and the persistent adherents (4318 [36.6%]). The probability of belonging to the not-adherent group was increased with female sex, low socioeconomic status, and polymedication and was reduced with a secondary indication for LDA use, such as diabetes, hypertension, and dementia, at least 4 consultations in the previous year, or 1 hospitalization or a cardiologist consultation in the 3 months before the index date. CONCLUSION This study provides a dynamic picture of adherence behaviors among new LDA users and underlines the presence of critical trajectories that intervention could target to improve adherence.
Collapse
Affiliation(s)
- Aya Ajrouche
- Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), INSERM, UMR 1123, ECEVE, CIC-P 1421, Paris, France
| | - Candice Estellat
- Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), INSERM, UMR 1123, ECEVE, CIC-P 1421, Paris, France
| | - Yann De Rycke
- Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), INSERM, UMR 1123, ECEVE, CIC-P 1421, Paris, France
| | - Florence Tubach
- Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), INSERM, UMR 1123, ECEVE, CIC-P 1421, Paris, France
| |
Collapse
|
13
|
Ajrouche A, De Rycke Y, Dalichampt M, Messika Zeitoun D, Hulot J, Estellat C, Tubach F. Reduced risk of cancer among low‐dose aspirin users: Data from French health care databases. Pharmacoepidemiol Drug Saf 2019; 28:1258-1266. [DOI: 10.1002/pds.4870] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 06/16/2019] [Accepted: 07/05/2019] [Indexed: 11/11/2022]
Affiliation(s)
- Aya Ajrouche
- Faculté de médecine Sorbonne Université, AP‐HP, Hôpital Pitié‐Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne Université INSERM, UMR 1123, ECEVE, CIC‐P 1421 Paris France
| | - Yann De Rycke
- Faculté de médecine Sorbonne Université, AP‐HP, Hôpital Pitié‐Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne Université INSERM, UMR 1123, ECEVE, CIC‐P 1421 Paris France
| | - Marie Dalichampt
- Caisse nationale d'assurance maladie des travailleurs salariés cnamts Paris France
| | | | - Jean‐Sebastien Hulot
- Faculté de médecine Sorbonne UniversitéSorbonne Université, INSERM, CIC‐1421 Paris France
| | - Candice Estellat
- Faculté de médecine Sorbonne Université, AP‐HP, Hôpital Pitié‐Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne Université INSERM, UMR 1123, ECEVE, CIC‐P 1421 Paris France
| | - Florence Tubach
- Faculté de médecine Sorbonne Université, AP‐HP, Hôpital Pitié‐Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi)Sorbonne Université INSERM, UMR 1123, ECEVE, CIC‐P 1421 Paris France
| |
Collapse
|
14
|
Bousquet PJ, Lefeuvre D, Tuppin P, BenDiane MK, Rocchi M, Bouée-Benhamiche E, Viguier J, Le Bihan-Benjamin C. Cancer care and public health policy evaluations in France: Usefulness of the national cancer cohort. PLoS One 2018; 13:e0206448. [PMID: 30379946 PMCID: PMC6209307 DOI: 10.1371/journal.pone.0206448] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Accepted: 10/13/2018] [Indexed: 01/31/2023] Open
Abstract
Background In the context of the national Cancer Plans of France that have changed the healthcare landscape, it has become necessary to better document and assess the related actions, and to promote research and understanding. The national cancer cohort, an exhaustive population-based cohort, was set up on the basis of the National Health Data System (SNDS) by the French National Cancer Institute. Objectives The aim is to describe the French national cancer cohort. Methods All people living in France (67 million population) with universal insurance coverage and diagnosed, treated or followed up for a cancer, such as survivors, are included and will be followed up for 25 years. It contains all healthcare consumptions and reimbursements (i.e. hospitalization, outpatient care, medication…) since 2010. Every year, around 650 000 new cases are included. Results From 2010 to 2015, 6.2 million subjects have been included. Most subjects were entered in 2010, in 2015 it concerned 0.6 million. In 2015, the median age was 65 [54–76]; 51% were women. The primary cancer organ could be attributed with certitude to 87% of the people. The most frequent locations were skin (16%), breast (15%), prostate (12%), colon-rectum (11%) and lung (9%). In 2015, 40% of included subjects underwent surgery for cancer, 16% chemotherapy at hospital and 11% at least one session of radiotherapy. Conclusion Based on SNDS, the cancer cohort has been designed to study cancer care use in the short-, medium- and long-term, and evaluate healthcare and public health policies.
Collapse
Affiliation(s)
- Philippe Jean Bousquet
- Survey, Monitoring and Assessment Department, Public Health and Healthcare Division, Institut National du Cancer (French National Cancer Institute—INCa), Boulogne Billancourt, France
- Economy and social science, health care systems and societies, Faculté de médecine, Marseille, France
- * E-mail:
| | - Delphine Lefeuvre
- Survey, Monitoring and Assessment Department, Public Health and Healthcare Division, Institut National du Cancer (French National Cancer Institute—INCa), Boulogne Billancourt, France
| | - Philippe Tuppin
- Caisse nationale d'assurance maladie des travailleurs salariés, département des études sur les pathologies et les patients (DEPP), Paris, France
| | - Marc Karim BenDiane
- Economy and social science, health care systems and societies, Faculté de médecine, Marseille, France
| | - Mathieu Rocchi
- Survey, Monitoring and Assessment Department, Public Health and Healthcare Division, Institut National du Cancer (French National Cancer Institute—INCa), Boulogne Billancourt, France
| | - Elsa Bouée-Benhamiche
- Survey, Monitoring and Assessment Department, Public Health and Healthcare Division, Institut National du Cancer (French National Cancer Institute—INCa), Boulogne Billancourt, France
| | - Jérôme Viguier
- Public Health and Healthcare Division, Institut National du Cancer (French National Cancer Institute—INCa), Boulogne Billancourt, France
| | - Christine Le Bihan-Benjamin
- Survey, Monitoring and Assessment Department, Public Health and Healthcare Division, Institut National du Cancer (French National Cancer Institute—INCa), Boulogne Billancourt, France
| |
Collapse
|
15
|
Kaguelidou F, Sommet A, Lapeyre-Mestre M. Use of French healthcare insurance databases in pediatric pharmacoepidemiology. Therapie 2018; 73:127-133. [DOI: 10.1016/j.therap.2017.11.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2017] [Accepted: 11/15/2017] [Indexed: 01/24/2023]
|
16
|
Conte C, Palmaro A, Grosclaude P, Daubisse-Marliac L, Despas F, Lapeyre-Mestre M. A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases. Medicine (Baltimore) 2018; 97:e9418. [PMID: 29480830 PMCID: PMC5943849 DOI: 10.1097/md.0000000000009418] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
The use of claims database to study lymphomas in real-life conditions is a crucial issue in the future. In this way, it is essential to develop validated algorithms for the identification of lymphomas in these databases. The aim of this study was to assess the validity of diagnosis codes in the French health insurance database to identify incident cases of lymphomas according to results of a regional cancer registry, as the gold standard.Between 2010 and 2013, incident lymphomas were identified in hospital data through 2 algorithms of selection. The results of the identification process and characteristics of incident lymphomas cases were compared with data from the Tarn Cancer Registry. Each algorithm's performance was assessed by estimating sensitivity, predictive positive value, specificity (SPE), and negative predictive value.During the period, the registry recorded 476 incident cases of lymphomas, of which 52 were Hodgkin lymphomas and 424 non-Hodgkin lymphomas. For corresponding area and period, algorithm 1 provides a number of incident cases close to the Registry, whereas algorithm 2 overestimated the number of incident cases by approximately 30%. Both algorithms were highly specific (SPE = 99.9%) but moderately sensitive. The comparative analysis illustrates that similar distribution and characteristics are observed in both sources.Given these findings, the use of claims database can be consider as a pertinent and powerful tool to conduct medico-economic or pharmacoepidemiological studies in lymphomas.
Collapse
Affiliation(s)
- Cécile Conte
- LEASP-UMR 1027, Inserm-University of Toulouse
- Medical and Clinical Pharmacology Unit
| | - Aurore Palmaro
- LEASP-UMR 1027, Inserm-University of Toulouse
- Medical and Clinical Pharmacology Unit
- CIC 1436, Toulouse University Hospital
| | - Pascale Grosclaude
- LEASP-UMR 1027, Inserm-University of Toulouse
- Claudius Regaud Institute, IUCT-O, Tarn Cancer Registry, Toulouse, France
| | - Laetitia Daubisse-Marliac
- LEASP-UMR 1027, Inserm-University of Toulouse
- Claudius Regaud Institute, IUCT-O, Tarn Cancer Registry, Toulouse, France
| | - Fabien Despas
- LEASP-UMR 1027, Inserm-University of Toulouse
- Medical and Clinical Pharmacology Unit
- CIC 1436, Toulouse University Hospital
| | - Maryse Lapeyre-Mestre
- LEASP-UMR 1027, Inserm-University of Toulouse
- Medical and Clinical Pharmacology Unit
- CIC 1436, Toulouse University Hospital
| |
Collapse
|